- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about RHHBY
Recent news which mentions RHHBY
Roche Posts Encouraging Follow-up Data From Tiragolumab/Tecentriq Trial In Lung Cancer
December 10, 2021
From Benzinga
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
December 07, 2021
From InvestorPlace
Europe Approves Roche's Tocilizumab For Patients With Severe COVID-19
December 07, 2021
From Benzinga
Immunocore' ImmTAC Candidate Shows Early Response In Ovarian And Head & Neck Cancer Patients
December 06, 2021
From Benzinga
Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November
December 04, 2021
From Motley Fool
Biden's New COVID-19 Plan Includes Reimbursement For Over The Counter, At-Home COVID Tests
December 03, 2021
From Benzinga
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
December 02, 2021
From Benzinga
52 Biggest Movers From Yesterday
December 01, 2021
From Benzinga
35 Stocks Moving In Tuesday's Mid-Day Session
November 30, 2021
From Benzinga
From Benzinga
As FINRA's OTC Bulletin Board Closes Down, OTC Markets Group Becomes the Main Gateway Into the Regulated Over-the-Counter Market
November 30, 2021
From Benzinga
Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?
November 28, 2021
From Motley Fool
Detecting Early Cancer Screening Stocks At An Early Stage Is Critical
November 22, 2021
From Benzinga
1 Cancer Stock on Buyout Watch in 2022
November 21, 2021
From Motley Fool
From Motley Fool
Ocugen Stock: Bull vs. Bear
November 20, 2021
From Motley Fool
Roche's Gavreto Conditionally Approved In Europe For RET Fusion-Positive Lung Cancer
November 19, 2021
From Benzinga
From Benzinga
From Benzinga
3 Biotech Stocks That Have More Than Tripled so far This Year
November 18, 2021
From Motley Fool
Why Atea Pharmaceuticals Stock Is Sinking Today
November 17, 2021
From Motley Fool
Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill
November 17, 2021
From Benzinga
From InvestorPlace
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
November 12, 2021
From Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
From Benzinga
EU Regulator Backs Regeneron-Roche's COVID-19 Drug
November 11, 2021
From Benzinga
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
From Benzinga
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
November 09, 2021
From Benzinga
These OTCQX & OTCQB Securities Had the Most Trading Activity in October
November 09, 2021
From Benzinga
Should You Buy Pfizer Stock After the Fantastic COVID-19 Pill News?
November 09, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.